Literature DB >> 30763746

Efficacy and Safety of Gamma Knife Radiosurgery for Meningiomas in Patients with Neurofibromatosis Type 2: A Long-Term Follow-Up Single-Center Study.

Faliang Gao1, Min Li1, Zheng Wang1, Lingfei Shi2, Lin Lou1, Jia Zhou3.   

Abstract

OBJECTIVE: To explore the efficacy and safety of Gamma Knife radiosurgery (GKRS) for meningiomas in patients with neurofibromatosis type 2 (NF2).
METHODS: A series of 35 consecutive patients with 99 meningiomas in our department were retrospectively included from January 2000 to December 2015. Clinical records, magnetic resonance images, and follow-up data were reviewed.
RESULTS: A total of 35 patients (25 women and 10 men) with 99 NF2-associated meningiomas were identified. All patients initially received GKRS. The patients' median age at the time of GKRS was 40 years (range, 16-61 years). The median prescription dose at the tumor margin was 13 Gy (range, 12-15 Gy). The median follow-up time was 96 months (range, 25-224 months). Twenty-nine patients received GKRS only once, and 6 patients received it multiple times. Six patients (17.1%) had radiation-related complications 7.5 ± 2.4 months after GKRS. Local control rates at 1, 3, and 5 years were 100%, 97.1%, and 90.6%, respectively. Distant control rates at 1, 3, and 5 years were 88.5%, 55.9%, and 45.5%, respectively. Five patients died of concomitant neurologic symptoms. No malignant transformation was observed during the follow-up periods in all 35 patients.
CONCLUSIONS: GKRS represents an effective and safe management strategy with minimal invasion for patients with NF2-associated meningiomas. Our data showed a high local control rate of NF2-associated meningiomas by GKRS; however, the distant control rate is low, especially in young patients. For these patients, retreatment with GKRS may still be the advisable method.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gamma knife; Meningioma; Neurofibromatosis type 2; Stereotactic radiosurgery; Tumor control

Year:  2019        PMID: 30763746     DOI: 10.1016/j.wneu.2019.01.211

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Skull Base Meningiomas in Patients with Neurofibromatosis Type 2: An International Multicenter Study Evaluating Stereotactic Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gautam U Mehta; Gregory P Lekovic; Jason P Sheehan
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

2.  Secondary malignancy following stereotactic radiosurgery for benign neurologic disease: A cohort study and review of the literature.

Authors:  Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak
Journal:  J Radiosurg SBRT       Date:  2020

3.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

4.  Multiple meningiomas arising within the same hemisphere associated with Li-Fraumeni syndrome.

Authors:  Christopher S Hong; E Zeynep Erson-Omay; Jennifer Moliterno
Journal:  Surg Neurol Int       Date:  2021-03-17

5.  Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gregory P Lekovic; Gautam U Mehta; Jason P Sheehan
Journal:  World Neurosurg       Date:  2020-11-03       Impact factor: 2.104

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.